Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27431248 | 0.91 | ADORA3 (0.53) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL27430559 | 0.89 | ADORA3 (0.49) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL27431176 | 0.87 | ADORA3 (0.53) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL27428840 | 0.87 | SLC29A1 (0.53) | ADORA3SLC29A1ADORA1 | |
| SCHEMBL27430074 | 0.87 | ADORA3 (0.51) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL27433981 | 0.87 | ADORA3 (0.51) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL27428243 | 0.86 | SLC29A1 (0.57) | ADORA3SLC29A1ADORA1 | |
| SCHEMBL27433457 | 0.84 | ADORA3 (0.53) | ADORA3SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL27436584 | 0.84 | ADORA3 (0.53) | ADORA3SLC29A1ADORA2AADORA2B | |
| SCHEMBL27436290 | 0.84 | ADORA3 (0.52) | ADORA3SLC29A1ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |